Atsena Therapeutics

Focus: Atsena Therapeutics is a newly founded (2024) gene therapy company headquartered in Durham, NC, focused on treating inherited retinal diseases through innovative genetic approaches. The company is pre-revenue and in early clinical stages with a lean operational footprint.

Gene Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Atsena Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Atsena Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

ATSN-101

Leber Congenital Amaurosis

Phase 1/2

Clinical Trials (1)

NCT03920007Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D

Phase 1/2

Help build intelligence for Atsena Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at a freshly founded gene therapy company with potential for rapid advancement and equity upside as the company scales from 2024 launch
Focused pipeline in high-unmet-need rare eye diseases (Leber Congenital Amaurosis, X-linked Retinoschisis) targeting patient populations with limited treatment options
Hiring across core functions (Clinical Development, Process Development, Analytical Development, Quality, Medical Affairs) suggests organized, multi-disciplinary build-out rather than chaotic startup

Watch Out For

No disclosed funding data, revenue, or cash position raises questions about runway, burn rate, and whether the company has secured Series A financing—critical unknowns for long-term stability
Pre-clinical publication record (0 publications) and only 2 early-stage Phase 1/2 trials suggest limited external validation, scientific credibility, or data readouts to drive investor confidence or career momentum

Generated by Claude from Atsena Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

ATSN-201

X-linked Retinoschisis

Phase 1/2

Clinical Trials (1)

NCT05878860ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis

Phase 1/2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2024

Portfolio: 2 clinical trials

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo